Better Therapeutics, Inc. BTTX
We take great care to ensure that the data presented and summarized in this overview for Better Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BTTX
View allLatest Institutional Activity in BTTX
Top Purchases
Top Sells
About BTTX
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Insider Transactions at BTTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2024
|
David P Perry Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
839,895
+25.79%
|
$0
$0.19 P/Share
|
|
Jan 09
2024
|
David P Perry Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
1,471,453
+48.27%
|
$0
$0.17 P/Share
|
|
Dec 18
2023
|
David P Perry Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+3.44%
|
-
|
|
Dec 18
2023
|
Leslie A. Miller Principal Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,587
+16.67%
|
-
|
|
Dec 18
2023
|
Andrew J. Armanino |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+18.0%
|
-
|
|
Dec 18
2023
|
Geoffrey M. Parker |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+0.36%
|
-
|
|
Dec 18
2023
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,362
+10.1%
|
-
|
|
Dec 18
2023
|
Risa J Lavizzo Mourey |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+21.43%
|
-
|
|
Dec 18
2023
|
Richard H Carmona |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+2.33%
|
-
|
|
Dec 18
2023
|
Elder Granger |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+8.65%
|
-
|
|
Dec 18
2023
|
Mark A. Berman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,362
+5.36%
|
-
|
|
Dec 18
2023
|
Frank Karbe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+10.61%
|
-
|
|
Jul 27
2023
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
1,233,045
+8.64%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
685,025
+39.99%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Frank Karbe Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
137,005
+24.19%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Elder Granger |
BUY
Open market or private purchase
|
Direct |
34,251
+48.86%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
274,010
+27.34%
|
$0
$0.73 P/Share
|
|
Jul 27
2023
|
Mark A. Berman Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
54,802
+12.37%
|
$0
$0.73 P/Share
|
|
May 16
2023
|
Elder Granger |
BUY
Open market or private purchase
|
Direct |
600
+27.27%
|
$0
$0.87 P/Share
|
|
Apr 10
2023
|
David P Perry Executive Chairman |
BUY
Open market or private purchase
|
Indirect |
4,969,697
+30.08%
|
$0
$0.82 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.45M shares |
|---|